Oncternal Therapeutics - Company Profile

Powered by

All the data and insights you need on Oncternal Therapeutics in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Oncternal Therapeutics Strategy Report

  • Understand Oncternal Therapeutics position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Oncternal Therapeutics: Overview

Select Item

Oncternal Therapeutics (Oncternal), formerly GTx Inc, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s has pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid lukemia and a ROR1-targeted CAR-T therapy candidate for treatment hematologic and solid tumors. It conducts preclinical development activities in the US and Europe. Oncternal is headquartered in San Diego, California, the US.

 Gain a 360-degree view of Oncternal Therapeutics and make more informed decisions for your business Gain a 360-degree view of Oncternal Therapeutics and make more informed decisions for your business Find out more
Headquarters United States of America
Address 12230 El Camino Real, Suite 230, San Diego, California, 92130
Website www.oncternal.com
Telephone 1 858 4341113
No of Employees 27
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange ONCT (NASD)
Revenue (2022) $785,000 -47.3% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 10.6% (2022 vs 2021)
Market Cap* $26.5M
Net Profit Margin (2022) XYZ -69.7% (2022 vs 2021)
* As of and is in US$
View Oncternal Therapeutics financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Oncternal Therapeutics premium industry data and analytics

40+

Clinical Trials

Determine Oncternal Therapeutics go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Oncternal Therapeutics’s relevant decision makers and contact details.

20+

Pipeline Drugs

Identify which of Oncternal Therapeutics’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Catalyst Calendar

Proactively evaluate Oncternal Therapeutics’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline
Cirmtuzumab:
Chronic Lymphocytic Leukemia (CLL)
XYZ
XYZ
XYZ
Understand Oncternal Therapeutics portfolio and identify potential areas for collaboration Understand Oncternal Therapeutics portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Oncternal Therapeutics Johnson & Johnson Pfizer Inc Gilead Sciences Inc TG Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Diego New Brunswick New York Foster City Morrisville
State/Province California New Jersey New York California North Carolina
No. of Employees 27 131,900 88,000 18,000 264
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
David F. Hale Chairman Executive Board 2019 74
James B. Breitmeyer, M.D., Ph.D. Chief Executive Officer; Director; President Executive Board 2019 69
Richard G. Vincent Chief Financial Officer Senior Management 2017 60
Rajesh Krishnan, PhD Chief Technology Officer Senior Management 2020 -
Salim Yazji, M.D. Chief Medical Officer Senior Management 2021 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Oncternal Therapeutics key executives to enhance your sales strategy Gain insight into Oncternal Therapeutics key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward